Login / Signup

Oxidative Stress and Menopausal Status: The Coronary Artery Risk Development in Young Adults Cohort Study.

Amir S HeraviErin Donelly MichosDi ZhaoBharath Ambale-VenkateshHenrique Doria De VasconcellosDonald Lloyd-JonesPamela J SchreinerJared P ReisColin WuCora E LewisJames M ShikanyStephen SidneyEliseo GuallarChiadi E NdumelePamela OuyangRon C HoogeveenJoao A C LimaR Dhananjay VaidyaWendy S Post
Published in: Journal of women's health (2002) (2022)
Background: Low endogenous estrogen concentrations after menopause may contribute to higher oxidative stress and greater cardiovascular disease (CVD) risk. However, differences in oxidative stress between similarly aged premenopausal and postmenopausal women are not well-characterized on a population level. We hypothesized that urinary isoprostane concentrations, a standard measure of systemic oxidative stress, are higher in women who have undergone menopause compared to premenopausal women. Methods and Results: We examined differences in urinary 8-isoprostane (iPF 2α -III) and 2,3-dinor-8-isoprostane (iPF 2α -III-M) indexed to urinary creatinine between 279 postmenopausal and 196 premenopausal women in the Coronary Artery Risk Development in Young Adults (CARDIA) study, using linear regression with progressive adjustment for sociodemographic factors and traditional CVD risk factors. Unadjusted iPF 2α -III-M concentrations were higher among postmenopausal compared to premenopausal women (Median [25th, 75th percentile]: 1762 [1178, 2974] vs. 1535 [1067, 2462] ng/g creatinine; p  = 0.01). Menopause was associated with 25.5% higher iPF 2α -III-M (95% confidence interval [6.5-47.9]) adjusted for age, race, college education, and field center. Further adjustments for tobacco use (21.2% [2.9-42.6]) and then CVD risk factors (18.8% [0.1-39.6]) led to additional partial attenuation. Menopause was associated with higher iPF 2α -III in Black but not White women. Conclusions: We conclude that postmenopausal women had higher oxidative stress, which may contribute to greater CVD risk. ClinicalTrials.gov Identifier: NCT00005130.
Keyphrases